A Novel Therapeutic Target in Inflammatory Uveitis: Transglutaminase 2 Inhibitor
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Our goal was to investigate the effects of inhibition of transglutaminase 2 (TGase 2) on endotoxin-induced uveitis (EIU)Methods: EIU was induced in female Lewis rats by single footpad injections of 200 μg of lipopolysaccharide (LPS). TGase 2 inhibitors were administered intraperitoneally 30 minutes before and at the time of LPS administration. Rats were sacrificed 24 hours after injection, and the effects of the TGase 2 inhibitors were evaluated by the number of intraocular inflammatory cells present on histologic sections and by measuring the TGase 2 activity and TGase products in the aqueous humor (AqH). TGase 2 substrates were also assayed in AqH from uveitis patients. Results: Clinical indications of EIU, the number of cells present on histologic sections, and TGase 2 activity in AqH increased in a time-dependent manner, peaking 24 hours after LPS injection. Inflammation in EIU was significantly reversed by treatment with TGase inhibitors. A 23-kDa cross-linked TGase substrate was identified in the AqH from EIU rats and uveitis patients. MALDI-TOF analysis showed that this substrate in uveitis patients was human Ig kappa chain C region. Conclusions: TGase 2 activity and its catalytic product were increased in the AqH of EIU rats. TGase 2 inhibition attenuated the degree of inflammation in EIU. Safe and stable TGase inhibitors may have great potential for the treatment of inflammatory uveitis.
Abstract
Purpose: Our goal was to investigate the effects of inhibition of transglutaminase 2 (TGase 2) on endotoxin-induced uveitis (EIU)Methods: EIU was induced in female Lewis rats by single footpad injections of 200 μg of lipopolysaccharide (LPS). TGase 2 inhibitors were administered intraperitoneally 30 minutes before and at the time of LPS administration. Rats were sacrificed 24 hours after injection, and the effects of the TGase 2 inhibitors were evaluated by the number of intraocular inflammatory cells present on histologic sections and by measuring the TGase 2 activity and TGase products in the aqueous humor (AqH). TGase 2 substrates were also assayed in AqH from uveitis patients. Results: Clinical indications of EIU, the number of cells present on histologic sections, and TGase 2 activity in AqH increased in a time-dependent manner, peaking 24 hours after LPS injection. Inflammation in EIU was significantly reversed by treatment with TGase inhibitors. A 23-kDa cross-linked TGase substrate was identified in the AqH from EIU rats and uveitis patients. MALDI-TOF analysis showed that this substrate in uveitis patients was human Ig kappa chain C region. Conclusions: TGase 2 activity and its catalytic product were increased in the AqH of EIU rats. TGase 2 inhibition attenuated the degree of inflammation in EIU. Safe and stable TGase inhibitors may have great potential for the treatment of inflammatory uveitis.
참고문헌 (21)
- Rosenbaum JT, "Endotoxin- induced uveitis in rats as a model for human disease", Nature, 286, pp.611~613 (1980)
- Cousins SW, "Endotoxin-induced uveitis in the rat: observations on altered vascular permeability, clinical findings, and histology", Exp Eye Res, 39, pp.665~676 (1984)
- Bhattacherjee P, "An evaluation of ocular inflammation following the injection of bacterial endotoxin into the rat footpad", Invest Ophthalmol Vis Sci, 2, pp.196~202 (1983)
- Lightman S, "Uveitis: management", Lancet, 338, pp.1501~1504 (1991)
- Kim EC, "Immunomodulatory therapy for the treatment of ocular inflammatory disease: evidence-based medicine recommendations for use", Int Ophthalmol Clin, 46, pp.141~164 (2006)
- Folk JE, "Transglutaminases", Methods Enzymol, 113, pp.358~375 (1985)
- Fesus L, "Transglutaminase 2: an enigmatic enzyme with diverse functions", Trends Biochem Sci, 27, pp.534~539 (2002)
- Kim SY, "Transglutaminases in disease", Neurochem Int, 40, pp.85~103 (2002)
- Bruce SE, "Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease", Clin Sci, 68, pp.573~579 (1985)
- D’Argenio G, "Transglutaminases in Crohn’s disease", Gut, 37, pp.690~695 (1995)
- Choi YC, "Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2", J Biol Chem, 275, pp.8703~8710 (2000)
- Lee J, "Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia", J Biol Chem, 279, pp.53725~53735 (2004)
- Suh GY, "A peptide with anti- transglutaminase activity decreases lipopolysaccharide-induced lung inflammation in mice", Exp Lung Res, 32, pp.43~53 (2006)
- Sohn J, "Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis", J Clin Invest, 111, pp.121~128 (2003)
- Karpuj MV, "Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine", Nat Med, 8, pp.143~149 (2002)
- Broekhuyse RM, "Experimental autoimmune anterior uveitis (EAAU), a new form of experimental uveitis. I. Induction by a detergent-insoluble, intrinsic protein fraction of the retinal pigment epithelium", Exp Eye Res, 52, pp.465~474 (1991)
- Kim SY, "Transglutaminase 2 in inflammation", Front Biosci, 11, pp.3026~3035 (2006)
- Bowness JM, "Increase in transglutaminase and its extracellular products in response to an inflammatory stimulus by lipopolysaccharide", Mol Cell Biochem, 169, pp.157~163 (1997)
- Park KC, "Transglutaminase 2 induces nitric oxide synthesis in BV-2 microglia", Biochem Biophys Res Commun, 323, pp.1055~1062 (2004)
- Smith RS, "Ultrastructural studies of the blood-aquous barrier. I. Transport of an electron-dense tracer in the iris and ciliary body of the mouse", Am J Ophthalmol, 71, pp.1066~1077 (1971)
- Shapiro AL, "Synthesis of excess light chains of gamma globulin by rabbit lymph node cells", Nature, 211, pp.243~245 (1966)